Supported By Philips Healthcare
New Strategies in Treating Respiratory Failure: NIV and HFNO as complementary therapy
Nicholas S. Hill, MD
Chief, Pulmonary & Critical Care and Sleep Division Pulmonary,
Critical Care and Sleep Division
Tufts Medical Center
Noninvasive ventilation (NIV) or the delivery of positive pressure ventilation delivered through a noninvasive interface has become more common as its benefits are increasingly recognized. NIV has proven efficacy for hypercapnic respiratory failure, especially that due to COPD exacerbations. High-flow nasal cannula (HFNO) comprises an air/oxygen blender, an active humidifier, a single heated circuit, and a nasal cannula. HFNO has shown promise to treat hypoxic respiratory failure. This webinar will explore a new strategy in the treatment of respiratory conditions. Specifically, this presentation will discuss how HFNO may play a useful complementary role during breaks from NIV.
Upon completion of this activity, the participant will be able to:
Nicholas S. Hill, MD
Nicholas S Hill, MD, is Professor of Medicine at Tufts University School of Medicine, and Chief of the Pulmonary & Critical Care and Sleep Division at Tufts Medical Center in Boston, MA. His primary research interests include the role of angiogenic factors in pulmonary vascular biology, therapeutic approaches for clinical pulmonary hypertension, and evaluating ways of delivering and testing the efficacy of noninvasive ventilation. Dr Hill has authored or coauthored more than 200 articles in peer-reviewed journals such as American Journal of Physiology, Respiratory Medicine, and Critical Care Medicine. He is a member of the American College of Chest Physicians, American Thoracic Society (also past president), American Association for the Advancement of Science, and Pulmonary Hypertension Association.
Continuing Education for Physicians, Nurses and Respiratory Therapists
This education activity is approved for 1.0 contact hour. This activity is jointly provided by SynAptiv and Saxe Healthcare Communications. SynAptiv is accredited by the Accreditation Council for Continuing Medical Education (ACCME) for 1 AMA PRA Category 1 Credit. Continuing Respiratory Care Education (CRCE) credit by the American Association of Respiratory Care, 9425 N. MacArthur Blvd. Suite 100, Irving, TX 75063.Provider approved by California Board of Nursing, Provider # 14477 and the Florida Board of Nursing Provider # 50-17032
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of SynAptiv and Saxe Healthcare Communications. SynAptiv is accredited by the ACCME to provide continuing medical education for physicians. SynAptivdesignates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Honoring the extraordinary efforts of respiratory therapists